Jazz Pharmaceuticals JAZZ Accrued Royalties (Current)
Accrued Royalties (Current) at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccruedRoyaltiesCurrent.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's accrued royalties (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Jazz Pharmaceuticals's accrued royalties (current)?
- Jazz Pharmaceuticals (JAZZ) reported accrued royalties (current) of $47.6M in Q1 2026.
- How has Jazz Pharmaceuticals's accrued royalties (current) changed year-over-year?
- Jazz Pharmaceuticals's accrued royalties (current) increased by 62.6% year-over-year, from $29.27M to $47.6M.
- What is the long-term trend for Jazz Pharmaceuticals's accrued royalties (current)?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's accrued royalties (current) has grown at a 25.3% compound annual growth rate (CAGR), from $15.23M to $47.1M.